Across TCGA pan-cancer cohorts, SIRPB2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SIRPB2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SIRPB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIRPB2 expression acts as an unfavorable survival marker.

BLCA, ACC, and LUAD are the cancer types where SIRPB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.115	0.575	<.001	18	view →
ACC	DFS	Median	All	0.089	0.666	.010	9	view →
LUAD	DFS	Median	II,III,IV	0.205	0.654	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SIRPB2 tumor-vs-normal RNA expression · all SIRPB2 data types